Ligand Pharmaceuticals Posts 48% Royalty Revenue Growth in 2025 — Ligand Pharmaceuticals Incorporated

Event summary

Ligand Pharmaceuticals reported a 48% increase in royalty revenue for 2025, driven by strong performance from partners like Travere Therapeutics and Merck.
Fourth-quarter 2025 revenues rose 39% year-over-year to $59.7 million, with royalties accounting for $50.5 million of that total.
The company reaffirmed its 2026 financial guidance, projecting $245-$285 million in revenues and adjusted earnings per diluted share of $8.00-$9.00.
Key product highlights include the successful out-licensing of Zelsuvmi and positive clinical trial results for Qtorin rapamycin and Tzield.
Ligand ended 2025 with $733.5 million in cash, cash equivalents, and short-term investments.

The big picture

Ligand's strong financial performance in 2025 underscores the value of its royalty-based business model, particularly in the biopharmaceutical sector. The company's ability to leverage partnerships with major players like Merck and Travere Therapeutics highlights its strategic positioning in the industry. As Ligand looks to 2026, its focus on expanding its royalty portfolio and advancing clinical programs will be critical in maintaining its growth momentum.

What we're watching

Royalty Portfolio Performance: How the continued success of key products like Filspari and Ohtuvayre will impact Ligand's royalty revenue streams in 2026.
Clinical Development: Whether the positive Phase 3 results for Qtorin rapamycin and the regulatory progress of Tzield will translate into commercial success.
Strategic Partnerships: The pace at which Ligand can secure new high-value partnerships to sustain its growth trajectory.